1991
Artículos
Alberto P, Mermillod B, Cocconi PG, Schneider M, Seeber S, Wagener DJ, et al. Results of the first ESMO examination in medical oncology, London 1989. Ann Oncol. 1991 Jan;2(1):9-12 [PubMed]
Ausejo Segura M, Cruz Cruz T, Grávalos C, García Marco D, Alberola Gómez-Escobar C, Herreros de Tejada A. Participation of a pharmacy service in a home chemotherapy programme. Farm Clín. 1991;8(2):184-8
.
1992
Artículos
Moreno Cerro AM, Martínez Tello FJ, De Juanes Pardo JR, Cortés-Funes H. Registro de tumores del Hospital 12 de Octubre. Estudio retrospectivo de los tumores malignos durante los años 1987-1989. Oncologia. 1992;15(9):404-13
Quoix EA, Giaccone G, Jassem J, Karnicka H, Wiatr E, Cortés-Funes H, et al. Epirubicin in previously untreated patients with small cell lung cancer: a phase II study by the EORTC Lung Cancer Cooperative Group. Eur J Cancer. 1992;28A(10):1667-70 [PubMed]
.
1993
Artículos
Mayordomo JI, Guerra JM, Guijarro C, García Prats MD, Gómez A, López Brea M, et al. Neoplasms of unknown primary site: a clinicopathological study of autopsied patients. Tumori. 1993;79(5):321-4
Mayordomo JI, Rivera F. Severe hypocalcaemia after treatment with oral clodronate and aminoglycoside. Ann Oncol. 1993 May;4(5):432-3 [PubMed]
Mayordomo JI, Rivera F, Díaz Puente MT, Lianes P, Cortés-Funes H. Re: Decision analysis of hematopoietic growth factor use in patients receiving cancer chemotherapy. J Natl Cancer Inst. 1993 Aug 4;85(15):1251-3 [PubMed]
Paz Ares L, Lianes P, Díaz Puente M, Rivera F, Passas J, Costas P, et al. CMV front-line chemotherapy in transitional bladder carcinoma. Ann Oncol. 1993;4(2):147-50
Congresos
Paz-Ares L, Lianes P, Cortés-Funes H. Late relapses in advanced Malignant Germ Cell Tumours (MGCT) treated with cisplatin based chemotherapy [doi]. En: Jones WG, Harnden P, Appleyard I, eds. Advances in the Biosciences Germ Cell tumours III. Exeter: Pergamon; 1993. p. 273-4 [Proceedings of the Third Germ Cell Tumour Conference Held (3. Leeds. 1993)]
Paz-Ares L, López Brea M, Rivera F, P Lianes P, Cortés-Funes H. Salvage therapy in refractory/relapsed germ cell tumours: etoposide, iphosphamide and cisplatin (VIP) [doi]. En: Jones WG, Harnden P, Appleyard I, eds. Advances in the Biosciences Germ Cell tumours III. Exeter: Pergamon; 1993. p. 439-440 [Proceedings of the Third Germ Cell Tumour Conference Held (3. Leeds. 1993)]
.
1994
Artículos
Colomer R, Lupu R, Bacus SS, Gelmann EP. erbB-2 antisense oligonucleotides inhibit the proliferation of breast carcinoma cells with erbB-2 oncogene amplification. Br J Cancer. 1994 Nov;70(5):819-25 [PubMed]
Del Campo JM, Felip E, Rubio D, Vidal R, Bermejo B, Colomer R, et al. Long-term survival in advanced ovarian cancer after cytoreduction and chemotherapy treatment. Gynecol Oncol. 1994 Apr;53(1):27-32 [PubMed]
Domínguez Ortega L, Cubedo Cervera R, Díaz Gallego E, Cortés-Funés H. Protection against chemotherapy-induced emesis with sleep. Lancet. 1994 May 21;343(8908):1298. doi: 10.1016/s0140-6736(94)92188-1 [PubMed]
García Prats MD, López Carreira M, Mayordomo JI, Ballestín C, Rivera F, Díaz Puente MT, et al. Leiomyosarcoma of the soft tissues in a patient with nevoid basal-cell carcinoma syndrome. Tumori. 1994 Oct 31;80(5):401-4 [PubMed]
Gil F, Lianes P, Kash K.M, Holland JC. Soporte psicológico, consejo genético y alto riesgo hereditario de cáncer. Oncologia. 1994;17(11):43-8
Le Chevalier T, Brisgand D, Douillard JY, Pujol JL, Alberola V, Monnier A, et al. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol. 1994 Feb;12(2):360-7 [PubMed]
Le Chevalier T, Pujol JL, Douillard JY, Alberola V, Monnier A, Riviere A, et al. A three-arm trial of vinorelbine (Navelbine) plus cisplatin, vindesine plus cisplatin, and single-agent vinorelbine in the treatment of non-small cell lung cancer: an expanded analysis. Semin Oncol. 1994 Oct;21(5 Suppl 10):28-33; discussion 33-4 [PubMed]
Mayordomo JI, Paz Ares L, Rivera F, López Brea M, López Martín E, Mendiola C, et al. Ovarian and extragonadal malignant germ-cell tumors in females: a single-institution experience with 43 patients. Ann Oncol. 1994;5(3):225-31.
Mayordomo Cámara JI, Guerra Vales JM. Hacia una evaluación de los pacientes con cáncer de origen desconocido basada en el diagnóstico histológico. Propuesta de un algoritmo. Med Clin (Barc). 1994;102(11):423-6.
Paz Ares L, Lianes P, Cortés Funes H. The management of non-seminomatous germ cell tumours (GCT). Ann Oncol. 1994;5(5):457-62.
.
1995
Artículos
Abad A, García P, Grávalos C, Tusquets I, Font A, Pérez G, et al. Sequential methotrexate, 5-fluorouracil (5-FU), and high dose leucovorin versus 5-FU and high dose leucovorin versus 5-FU alone for advanced colorectal cancer. A multi-institutional randomized trial. Cancer. 1995 Mar 15;75(6):1238-44 [PubMed]
Boogaerts M, Cavalli F, Cortés-Funes H, Gatell JM, Gianni AM, Khayat D, et al. Granulocyte growth factors: achieving a consensus. Ann Oncol. 1995 Mar;6(3):237-44 [PubMed]
Colomer R. Genes en cáncer de mama: aplicaciones actuales y futuras. Revis Cancer. 1995;9(4):144-52
Felip E, Del Campo JM, Rubio D, Vidal MT, Colomer R, Bermejo B. Overexpression of c-erbB-2 in epithelial ovarian cancer. Prognostic value and relationship with response to chemotherapy. Cancer. 1995 Apr 15;75(8):2147-52 [PubMed]
Hidalgo M. Comparative study of infectious complications of different types of chronic central venous access devices. Cancer. 1995 Jan 1;75(1):132-3 [PubMed]
Hitt R, Hornedo J, Colomer R, Mendiola C, Brandáriz A, Sevilla E, et al. A phase I/II study of paclitaxel plus cisplatin as first-line therapy for head and neck cancers: preliminary results. Semin Oncol. 1995;22(6 Suppl 15):50-4
Hornedo J, Hidalgo M, Trigo M. Indicaciones de los factores de crecimiento hematopoyético en el manejo de las complicaciones infecciosas de la quimioterapia. Inflam Regul Crecim Cel. 1995;6(Nº Espec.):55-60
Mayordomo JI, Rivera F, Cortés-Funes H. Colony-stimulating factors for adjunctive therapy of infections in neutropenic cancer patients. Support Care Cancer. 1995 Jan;3(1):84-5 [PubMed]
Mayordomo JI, Rivera F, Díaz Puente MT, Lianes P, Colomer R, López Brea M, et al. Improving treatment of chemotherapy-induced neutropenic fever by administration of colony-stimulating factors. J Natl Cancer Inst. 1995;87(11):803-8
Ruiz A, Lianes P, Cortés-Funes H. Quimioterapia a altas dosis en el tratamiento de los tumores de células germinales. Situación actual, perspectivas futuras. Oncologia. 1995;18(11):28-38
.
1996
Artículos
Abad A, Grávalos C, Font A, Molina F, Díaz Puente MT, Fabregat X, et al. Phase II study of Mitonafide in advanced and relapsed colorectal cancer. Invest New Drugs. 1996;14(2):223-5 [PubMed]
Domínguez Ortega L, Cubedo Cervera R, Cortés Funés H, Díaz Gállego E. Sleep protects against chemotherapy induced emesis. Cancer. 1996;77(8):1566-70
Gatzemeier U, Shepherd FA, Le Chevalier T, Weynants P, Cottier B, Groen HJ, et al. Activity of gemcitabine in patients with non-small cell lung cancer: a multicentre, extended phase II study. Eur J Cancer. 1996 Feb;32A(2):243-8 [PubMed]
Hidalgo M, Benito J, Colomer R, Paz-Ares L. Recall reaction of a severe local peripheral neuropathy after paclitaxel extravasation. J Natl Cancer Inst. 1996;88(18):1320
Hidalgo M, Lumbreras C, Aguado JM. Síndromes linfoproliferativos asociados al virus de Epstein-Barr en receptores de trasplante de órganos. Med Clin (Barc). 1996;107(8):310-6
Hidalgo M, Paz-Ares L. Cáncer y SIDA: una extraña pareja. Med Clin (Barc). 1996;106(17):659-60
Hornedo J, Cortés-Funes H. The role of high dose chemotherapy in adult solid tumours other than breast cancer. Ann Oncol. 1996;7 Suppl 2:23-30 [PubMed]
Hornedo J, Hidalgo M, Trigo JM. Indicaciones de los factores de crecimiento hematopoyético en el manejo de las complicaciones infecciosas de la quimioterapia. Inflam Regul Crecim Cel. 1996;7(2):106-10
.
1997
Artículos
Barnadas A, Mendiola C, Casado A, Villar A, Jimeno J, Clerigue M, et al. Combination of oral idarubicin and prednimustine in advanced breast cancer: a phase II study. Eur J Cancer. 1997 Feb;33(2):312-5 [PubMed]
Colomer R, Aparicio J, Montero S, Guzmán C, Larrodera L, Cortés-Funes H. Low levels of basic fibroblast growth factor (bFGF) are associated with a poor prognosis in human breast carcinoma. Br J Cancer. 1997;76(9):1215-20.
Cortés-Funes H, Aisner J. Paclitaxel in head and neck cancer and other tumor types: chairmen’s introduction. Semin Oncol. 1997;24(1 Suppl 2):S51-7
Cortés-Funes H, Martin C, Abratt R, Lund B. Safety profile of gemcitabine, a novel anticancer agent, in non-small cell lung cancer. Anticancer Drugs. 1997 Jul;8(6):582-7 [PubMed]
Fernández Miranda C, Schoebel N, Angulo A, Paz-Ares L, Lianes P, Del Palacio A. Evolución a largo plazo de los lípidos séricos y del índice de masa corporal en varones con cáncer testicular tratados con quimioterapia. Rev Clin Esp. 1997;197(7):490-3
García Carbonero R, Hidalgo M, Paz-Ares L, Calzas J, Gómez H, Guerra JA, et al. Patient selection in high-dose chemotherapy trials: relevance in high-risk breast cancer. J Clin Oncol. 1997;15(10):3178-84
Hidalgo M, Hornedo J, Lumbreras C, Trigo JM, Gómez C, Perea S, et al. Lack of ability of ciprofloxacin-rifampin prophylaxis to decrease infection-related morbidity in neutropenic patients given cytotoxictherapy and peripheral blood stem cell transplants. Antimicrob Agents Chemother. 1997;41(5):1175-7.
Hidalgo M, Paz-Ares L, Rivera F, Lianes P, Huidobro G, Ruiz A, et al. Mediastinal non-seminomatous germ cell tumours (MNSGCT) treated with cisplatin-based combination chemotherapy. Ann Oncol. 1997;8(6):555-9.
Hitt R, Hornedo J, Colomer R, Hidalgo M, Brandáriz A, Peña M, et al. Study of escalating doses of paclitaxel plus cisplatin in patients with inoperable head and neck cancer. Semin Oncol. 1997;24(1 Suppl2):S58-64
Hitt R, Paz Ares L, Hidalgo M, Colomer R, Brandáriz A, Peña M, et al. Phase I/II study of paclitaxel/cisplatin as first-line therapy for locally advanced head and neck cancer. Semin Oncol. 1997;24(6 Suppl 19):S20-24
International Germ Cell Cancer Collaborative Group. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. . J Clin Oncol. 1997;15(2):594-603
Le Chevalier T, Gottfried M, Gatzemeier U, Shepherd F, Weynants P, Cottier B, et al. Etude multicentrique de phase II de la gemcitabine dans les cancers bronchiques non à petites cellules (CBNPC) [A phase II multicenter study of gemcitabine in non small cell lung cancers]. Bull Cancer. 1997 Mar;84(3):282-8 [PubMed]
Meneses G, Delgado MA, Pérez Machado MA, Prieto A, Alonso R, Carrión F, et al. Thymostimulin increases natural cytotoxic activity in patients with breast cancer. Int J Immunopharmacol. 1997 Apr;19(4):187-93 [PubMed]
Paz Ares L, Lahuerta J, Montes A. Tratamiento intensivo del mieloma múltiple con soporte de progenitores de la hematopoyesis. Med Clin (Barc). 1997;108(6):226-9.
Wasserman E, Hidalgo M, Hornedo J, Cortés-Funes H. Octreotide (SMS 201-995) for hematopoietic support-dependent high-dose chemotherapy (HSD-HDC)-related diarrhoea: dose finding study and evaluation of efficacy. Bone Marrow Transplant. 1997;20(9):711-4.
.
1998
Artículos
Calzas J, Lianes P, Cortés Funes H. Patología del corazón de origen extracardiaco (VII). Corazón y neoplasias. Rev Esp Cardiol. 1998;51(4):314-31.
Castellano D, Lianes P, Paz Ares L, Hidalgo M, Guerra JA, Gómez Martín C, et al. A phase II study of a novel gemcitabine plus cisplatin regimen administered every three weeks for advanced non-small-cell lung cancer. Ann Oncol. 1998;9(4):457-9
Díaz Rubio E, Sastre J, Zaniboni A, Labianca R, Cortés-Funes H, de Braud F, et al. Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: a phase II multicentric study. Ann Oncol. 1998 Jan;9(1):105-8 [PubMed]
García Carbonero R, Paz Ares L, Arcediano A, Lahuerta J, Bartolomé A, Cortés Funes H. Favorable prognosis after late relapse of Hodgkin’s disease. Cancer. 1998;83(3):560-5
García Patińo E, Gomendio B, Silva JM, García JM, Provencio M, Pérez Carrión R, et al. Detection of BRCA1 gene mutations in families with breast cancer patients and their healthy relatives. Int J Oncol. 1998 Aug;13(2):275-9 [PubMed]
Giaccone G, Splinter TA, Debruyne C, Kho GS, Lianes P, van Zandwijk N, et al. Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer. The European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol. 1998 Jun;16(6):2133-41 [PubMed]
Gómez H, Colomer R. Tratamiento del linfoma en el anciano. Med Clin (Barc). 1998 May 2;110(15):574-5 [PubMed]
Gómez H, Hidalgo M, Casanova L, Colomer R, Pen DL, Otero J, et al. Risk factors for treatment-related death in elderly patients with aggressive non-Hodgkin’s lymphoma: results of a multivariate analysis. J Clin Oncol. 1998 Jun;16(6):2065-9 [PubMed]
Hidalgo M, Mendiola C, López Vega JM, Castellano D, Méndez M, Batiste Alentón E, et al. A multicenter randomized phase II trial of granulocyte-colony stimulating factor-supported, platinum-based chemotherapy with flexible midcycle cisplatin administration in patients with advanced ovarian carcinoma. PSAMOMA Cooperative Group, Spain. Cancer. 1998;83(4):719-25.
Hitt R, Castellano D, Hidalgo M, García Carbonero R, Peña M, Brandáriz A, et al. Phase II trial of cisplatin and gemcitabine in advanced squamous-cell carcinoma of the head and neck. Ann Oncol. 1998;9(12):1347-9.
Montero S, Guzmán C, Cortés Funes H, Colomer R. Angiogenin expression and prognosis in primary breast carcinoma. Clin Cancer Res. 1998;4(9):2161-8
Pronk LC, Hilkens PH, van den Bent MJ, van Putten WL, Stoter G, Verweij J. Corticosteroid co-medication does not reduce the incidence and severity of neurotoxicity induced by docetaxel. Anticancer Drugs. 1998 Oct;9(9):759-64 [PubMed]
Pronk LC, Schrijvers D, Schellens JH, de Bruijn EA, Planting AS, Locci-Tonelli D, et al. Docetaxel and ifosfamide in patients with advanced solid tumors: results of a phase I study. Semin Oncol. 1998 Feb;25(1 Suppl 2):23-8 [PubMed]
Ramia JM, Alcalde J, Dhimes P, Cubedo R. Metastasis from choriocarcinoma of the mediastinum producing acute appendicitis. Dig Dis Sci. 1998;43(2):332-4
.
1999
Artículos
Cardenal F, López Cabrerizo MP, Antón A, Alberola V, Massuti B, Carrato A, et al. Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 1999 Jan;17(1):12-8 [PubMed]
Crown J, Coiffier B, Cortés-Funes H, Guillaume T, Kanz L, Kvalheim G, et al. ESTIC position paper: high-dose chemotherapy for breast cancer, investigation should continue. Ann Oncol. 1999 Aug;10(8):903-5 [PubMed]
Hasbini A, Mahjoubi R, Fandi A, Chouaki N, Taamma A, Lianes P, et al. Phase II trial combining mitomycin with 5-fluorouracil, epirubicin, and cisplatin in recurrent and metastatic undifferentiated carcinoma of nasopharyngeal type. Ann Oncol. 1999 Apr;10(4):421-5 [PubMed]
Hidalgo M, Castellano D, Paz-Ares L, Grávalos C, Díaz Puente M, Hitt R, Alonso S, Cortés Funes H. Phase I-II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer. J Clin Oncol. 1999;17(2):585-92.
Hidalgo M, Hornedo J, Lumbreras C, Trigo JM, Colomer R, Perea S, Gómez C, Ruiz A, García Carbonero R, Cortés Funes H. Outpatient therapy with oral ofloxacin for patients with low risk neutropenia and fever: a prospective, randomized clinical trial. Cancer. 1999;85(1):213-9
Lassaletta L, Brandáriz JA, Benito A, De la Cruz J, Gómez C, Ballestín C, et al. p53 expression in locally advanced pharyngeal squamous cell carcinoma. Arch Otolaryngol Head Neck Surg. 1999 Dec;125(12):1356-9 [PubMed]
Lassaletta L, Brandáriz JA, Benito A, Gómez C, Ballestín C, Hitt R, De la Cruz J, Álvarez-Vicent JJ. Detección de proteína p53 en tumores avanzados de cabeza y cuello. Acta Otorrinolaringol Esp. 1999;50(8):613-8
Montero S, Lloveras B, Cortés-Funes H, Colomer R. Correspondence re: S. Shimoyama et al., increased serum angiogenin concentration in colorectal cancer is correlated with cancer progression. Clin. Cancer Res., 5: 1125-1130, 1999. Clin Cancer Res. 1999 Nov;5(11):3722-3 [PubMed]
Perea S, Hidalgo M, Arcediano A, Ramos MJ, Gómez C, Hornedo J, Lumbreras C, Folgueira D, Corté Funes H, Rodríguez Noriega A. Incidence and clinical impact of fluoroquinolone-resistant Escherichia coli in the faecal flora of cáncer patients treated with high dose chemotherapy and ciprofloxacin prophylaxis. J Antimicrob Chemother. 1999;44(1):117-20
Pronk LC, van Putten WL, van Beurden V, de Boer-Dennert M, Stoter G, Verweij J. The venotonic drug hydroxyethylrutosiden does not prevent or reduce docetaxel-induced fluid retention: results of a comparative study. Cancer Chemother Pharmacol. 1999;43(2):173-7 [PubMed]
Reyes E, García Castro I, Esquivel F, Hornedo J, Cortés-Funes H, Solovera J, et al. Granulocyte colony-stimulating factor (G-CSF) transiently suppresses mitogen-stimulated T-cell proliferative response. Br J Cancer. 1999 Apr;80(1-2):229-35 [PubMed]
Valentín V, Murillo M, Azcoitia B, Ausejo M, Carretero Y, Cayuela PP. Control del dolor y prescripción de medicamentos en un programa de atención domiciliaria al paciente oncológico terminal. Oncologia. 1999;22(1):49-56
Voûte PA, Souhami RL, Nooij M, Somers R, Cortés-Funes H, van der Eijken JW, et al. A phase II study of cisplatin, ifosfamide and doxorubicin in operable primary, axial skeletal and metastatic osteosarcoma. European Osteosarcoma Intergroup (EOI). Ann Oncol. 1999 Oct;10(10):1211-8 [PubMed]
.
2000
Artículos
Aebi S, Gelber S, Castiglione-Gertsch M, Gelber RD, Collins J, Thürlimann B, et al. Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer? Lancet. 2000;355(9218):1869-74 [doi]
Bellmunt J, Guillem V, Paz-Ares L, González Larriba JL, Carles J, Albanell J, et al. Gemcitabine/paclitaxel-based three-drug regimens in advanced urothelial cancer. Eur J Cancer. 2000;36(Suppl 2):17-25 [doi]
Bellmunt J, Guillem V, Paz-Ares L, González-Larriba JL, Carles J, Batiste-Alentorn E, et al. Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. Spanish Oncology Genitourinary Group. J Clin Oncol. 2000;18(18):3247-55 [doi]
Castellano D, Hitt R, Cortés Funes H, Romero A, Rodríguez Peralto JL. Side effects of chemotherapy. Case 2. Radiation recall reaction induced by gemcitabine. J Clin Oncol. 2000;18(3):695-6
Colomer R, Llombart A, Lluch A, Ojeda B, Barnadas A, Carañana V, Fernández Y, De Paz L, Guillem V, Alonso S. Paclitaxel/gemcitabine administered every two weeks in advanced breast cancer: preliminary results of a phase II trial. Semin Oncol. 2000;27(1 Suppl 2):20-4
Colomer R, Montero S, Lluch A, Ojeda B, Barnadas A, Casado A, Massutí B, Cortés Funes H, Lloveras B. Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer. Clin Cancer Res. 2000;6(6):2356-62
De Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000 Aug;18(16):2938-47 [PubMed]
Gómez Martín C, Solá C, Hornedo J, Perea S, Lumbreras C, Valentí V, Arcediano A, Rodríguez M, Salazar R, Cortés Funes H, Hidalgo M. Rifampin does not improve the efficacy of quinolone antibacterial prophylaxis in neutropenic cáncer patients: results of a randomized clinical trial. J Clin Oncol. 2000;18(10):2126-34
Lhommé C, Vermorken JB, Mickiewicz E, Chevalier B, Álvarez A, Mendiola C, et al. Phase II trial of vinorelbine in patients with advanced and/or recurrent cervical carcinoma: an EORTC Gynaecological Cancer Cooperative Group Study. Eur J Cancer. 2000 Jan;36(2):194-9 [PubMed]
Lluch A, Ojeda B, Colomer R, Barnadas A, Massuti B, Casado A, et al. Doxorubicin and paclitaxel in advanced breast carcinoma: importance of prior adjuvant anthracycline therapy. Cancer. 2000;89(11):2169-75 [doi]
Piccart MJ, Green JA, Lacave AJ, Reed N, Vergote I, Benedetti-Panici P, et al. Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: A randomized phase II study of the European Organization for Research and Treatment of Cancer Gynecology Group. J Clin Oncol. 2000 Mar;18(6):1193-202 [PubMed]
Pronk LC, Vasey P, Sparreboom A, Reigner B, Planting AS, Gordon RJ, et al. A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumours. Br J Cancer. 2000;83(1):22-9 [doi]
Trigo JM, Tabernero JM, Paz Ares L, García Llano JL, Mora J, Lianes P, Esteban E, Salazar R, López López JJ, Cortés Funes H. Tumor markers at the time of recurrence in patients with germ cell tumors. Cancer. 2000;88(1):162-8
Valentí Moreno V, Tabernero Caturla J, Villavicencio Mavrich H, Paz-Ares L, Santomé Couto L. Diagnóstico y manejo del carcinoma «in situ» testicular [Diagnosis and management of carcinoma in situ of the testis]. Arch Esp Urol. 2000;53(6):443-6
La Biblioteca recopila las publicaciones del H12O en... 1991-2000 